Amphastar Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / January 2, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Dr. Jack Zhang,...
RANCHO CUCAMONGA, CA / ACCESSWIRE / January 2, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Dr. Jack Zhang,...
Pilot study for ANGLE's Portrait HER2 assay in Phase II study of HER2 targeting antibody-drug conjugate, BB-1701GUILDFORD, SURREY / ACCESSWIRE...
SOUTH SAN FRANCISCO, Calif., Dec. 29, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing...
STOCKHOLM, SWEDEN / ACCESSWIRE / December 29, 2023 / Promore Pharma (STO:PROMO)(FRA:8T0) Promore Pharma AB, under change of name to...
STOCKHOLM, SWEDEN / ACCESSWIRE / December 29, 2023 / iZafe Group (STO:IZAFE-B) iZafe Group AB ("iZafe Group") announces today that...
FORT MYERS, FL / ACCESSWIRE / December 28, 2023 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading oncology testing services...
Company adds further expertise in medical device industry R&D, regulatory affairs and commercializationMINNEAPOLIS, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Inspire...
- Company’s co-development partner, Giiant Pharma, Inc. (“Giiant”), receives funding as part of previously announced grant from the US Crohn’s...
Awarded additional $6.7 million to advance NexoBrid as a non-surgical field care solution; R&D project budget increased to $14.4 millionYAVNE,...
WALTHAM, Mass., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a...
SEATTLE, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to...
In 2023, Cosmos Health concluded multiple acquisitions, including Cana Laboratories, the distribution network owned by Bikas GP, and ZipDoctor.These acquisitions...
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - December 27, 2023) - BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV)...
- Primary Endpoint of Safety and Efficacy Met with Clinical Activity and Increased Survival Observed - - 70.3 Weeks Median...
Company to retain economic interest in biotherapeutic asset while removing cash burn from development and commercialization costsREDWOOD CITY, Calif., Dec....
In an acute colitis model, data show statistically significant knockdown of elevated levels of serum TNFα, reductions in tissue TNFα...
No dose limiting toxicities were reported in the first cohort of ultra-high concentration of nitric oxide administered at 25,000 parts...
Statistically Significant and Clinically Meaningful Increasein Primary Efficacy Endpoint at 24 Weeks of Treatment; Improvement Consistent Across All Prespecified Subgroups...
WAYNE, Pa. and ROCKVILLE, Md., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced a 1-for-240...
VANCOUVER, British Columbia, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or...